RADIO AND SATELLITE INTERVIEW OPPORTUNITY THURSDAY, JUNE 27th, 2019, 7:30-NOON ET FDA APPROVES FIRST-OF-ITS-KIND TREATMENT FOR METASTATIC BREAST CANCER PATIENTS WITH A SPECIFIC MUTATION Breast Cancer Expert and Patient Advocate Discuss Why Mutations Matter for Postmenopausal Women, and Men, Living with Metastatic Breast Cancer AVAILABLE FOR INTERVIEW Dr. Virginia Kaklamani, Professor of Hematology/Oncology at UT Health San Antonio Shirley Mertz, President of the Metastatic Breast Cancer Network (MBCN) Americans are more aware than ever about genetic testing and mutations in metastatic breast cancer, such as the increased risks associated with the BRCA1/2 gene. What they may not know is that tumors can develop mutations that impact how the breast cancer responds to treatment. Following a recent FDA approval of a new medicine, postmenopausal women and men living with HR+/HER2- metastatic breast cancer who have progressed on or after an endocrine-based regimen may be eligible for treatment if a PIK3CA mutation is detected. The FDA recently approved a new medication to treat women who have gone through menopause and men who haveHR+/HER2- advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic). Thisimportant milestone marks the first time physicians are able to test advanced or metastatic breast cancer patients for aspecific mutation and develop a personalized treatment plan. Mutations of this kind occur in approximately 40% of HR+/HER2- breast cancers, the most common type of breast cancer. The mutations may lead to tumor growth, cause resistance to endocrine therapies and result in a poor overall prognosis. Dr. Virginia Kaklamani, Professor of Hematology/Oncology at UT Health San Antonio , is available to discuss this newtreatment option for patients. Shirley Mertz, President of the Metastatic Breast Cancer Network (MBCN), is also available to share her perspective on the importance for patients of knowing their breast cancer type. SUGGESTED INTERVIEW QUESTIONS Shirley and Dr. Kaklamani, why is this FDA approval significant? Shirley, in your experience as an advocate, how does HR+/HER2- metastatic breast cancer impact the lives of men and postmenopausal women? Shirley, what does it mean to have a new treatment option available for patients living with HR+/HER2- metastatic breast cancer with a PIK3CA mutation? Dr. Kaklamani, how do PIK3CA mutations affect prognosis and progression in HR+/H